CCDC117

Across TCGA pan-cancer cohorts, CCDC117 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC117 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCDC117 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CCDC117 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and OV are the cancer types where CCDC117 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.836	0.431	.017	7	view →
LUAD	OS	Median	II,III,IV	0.785	0.505	.015	6	view →
OV	DFS	Median	All	0.604	0.882	.044	4	view →
UCEC	DFS	Tertile	All	1.000	0.916	.049	2	view →
CCRCC	OS	Quartile	All	0.655	1.000	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC117–PDAC (OS)

Open the PDAC breakdown →